Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives $21.13 Consensus Target Price from Analysts

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $21.1250.

TLX has been the subject of several research analyst reports. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Citigroup increased their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $7.85 on Thursday. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $20.00. The company has a 50 day moving average of $7.32 and a 200-day moving average of $8.80. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). As a group, analysts expect that Telix Pharmaceuticals will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at approximately $89,000. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at approximately $111,000. Vident Advisory LLC bought a new position in Telix Pharmaceuticals in the 4th quarter worth approximately $204,000. Finally, IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.